Antibiotice Iasi Shareholders OK EUR25M Funding from EIB

10.31.2023 By Eduard Ivanovici

The extraordinary general meeting of shareholders convened by drug maker Antibiotice Iasi on October 30 approved the signing of a financing contract worth EUR25 million euro, i.e. RON23 million calculated at a rate of RON4.9202/EUR.

To read the full story, please login. Not a member? Subscribe here.

Reveal Romania! Business news & views.
Find out all you need by reading the entire story
To invest in Romania, you need to find out about its opportunities.
To close a strategic partnership with a Romanian company, you need to learn about its market position and whether it is a trustworthy partner
To grow here, you need to be informed

Subscribe now
Only 50 euros/month (VAT not included)
Get access to reports, news and statistics in the main sectors of Romania’s economy. Follow the strategic moves of companies operating in Romania. We will keep you updated on the latest business events.
Contact: E: newsroom@zfenglish.com (newsroom), marketing@zfenglish.com (Marketing & PR), sales@zfenglish.com (subscriptions)
T: 0040-318.256.431 (Newsroom)
0040-318.256.158, 0040-318.256.408 (Subscriptions Department)
0040-318.256.469, 0040-318.256.470 (Advertising Sales Department)
0040-318.256.427, 0040-318.256.129 (Marketing & PR)

LOGIN / Lost password?

 
Keywords:
Antibiotice Iasi
, funding
, EIB